The peripheral iVolution Stent is a stent made out of a nickel/titanium alloy (nitinol). The stent is loaded into the delivery system that will release it at the site of implantation.
The stent is self-expanding, achieving the diameter it has been designed for once it is released from the delivery device. From that moment on, it remains implanted in the artery, exerting a continuous force on the artery wall to stay open.
The stent design is based on a plurality of undulating rings that extend axially without connection bridges forming an open-cell stent.
The metal at the stent ends is less dense in artery coverage, and incorporates a series of radiopaque markers to visualize the stent once expanded.
The stent is made from a nitinol tube that is cut using a laser technique and then expanded to the required final diameter. The surface is then polished to achieve a smooth, shiny finish.
The stent delivery system is a coaxial catheter with triple sheath design, consisting of:
The system ends in a soft, atraumatic tip to avoid damaging the artery during its advance
See IFU for further information. Available to download.
The peripheral self-expanding stent system iVolution is indicated for the treatment of de novo or restenotic atherosclerotic lesions in peripheral arteries located under the aortic arch and for palliation of biliary tract malignant stenosis with a nominal diameter ranging from 4.5 and 9.5 mm.
Click to enlarge
EVOLUTION trial. The objective of this clinical investigation is to evaluate the short-term (up to 12 months) outcome of treatment by means of the self-expanding iVolution nitinol stent in symptomatic (Rutherford 2-4) femoropopliteal arterial stenotic or occlusive lesion of ≤ 15 cm. The study involves 120 patients and is coordinated by Dr. Marc Bosiers in Belgium. Primary endpoint is the Primary Patency at 12 months, defined as freedom from >50% restenosis at 12 months as indicated by duplex ultrasound in the target vessel with no reintervention. Secondary endpoints are: Primary Patency rate at 1 & 6-month follow-up, Technical success defined as the ability to cross and stent the lesion to achieve residual angiographic stenosis no greater than 30% and residual stenosis less than 50% by duplex imaging, Freedom from Target Lesion Revascularization (TLR) at 1, 6 & 12-month follow-up, improvement of Rutherford stage in one class or more at 1, 6 & 12-month follow-up and serious adverse effects.